RIGI and cancer: Published studies (Poeck et al., 2008; Besch et al., 2009; Kübler et al., 2010; Ellermeier et al., 2013; Duewell et al., 2014; Chiappinelli et al., 2015; Roulois et al., 2015; Yu et al., 2016) have reported that RIG-I ligands could trigger RIG-I activation either in tumor cells, directly leading to cancer cell apoptosis, or in immune cells (e.g., DCs) to induce cancer immunogenic cell death.